Details of the Drug Combinations

General Information of This Drug (ID: DMXI8X0)

Drug Name

Mitapivat DMXI8X0

Synonyms

AG-348

Indication

Disease Entry	ICD 11	Status	REF
Hereditary haemolytic anemia	3A10.3	Approved	[1]
Pyruvate kinase deficiency	5C53.00	Phase 2	[2]
------------------------------------------------------------------------------------

Structure

3D MOL

2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

7 Investigative Drug Combination(s) Consisting of This drug

Normalized Drug Combination Synergy Score

Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Evacetrapib + Mitapivat	DCAH30C	Evacetrapib	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[3]
Mitapivat + Panobinostat	DC27EKX	Panobinostat	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[3]
Mitapivat + IT-141	DCX1A9W	IT-141	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[3]
Mitapivat + Mitomycin	DCLGOAQ	Mitomycin	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[3]
Mitapivat + Vincristine	DC7JEQH	Vincristine	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[3]
Mitapivat + BMS-754807	DCD4B0T	BMS-754807	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[3]
Mitapivat + Teriflunomide	DCRYP69	Teriflunomide	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[3]
------------------------------------------------------------------------------------


⏷ Show the Full List of 7 DrugCom(s)

References

1	FDA Approved Drug Products from FDA Official Website. 2022. Application Number: 216196.
2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3	Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.